Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $13.00 from $16.00 previously

Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $16.00 from $28.00 previously

HC Wainwright & Co. reiterated coverage of BiomX with a rating of Buy and set a new price target of $10.00 from $20.00 previously

Ladenburg Thalmann initiated coverage of BiomX with a rating of Buy and set a new price target of $25.00

SCHEDULE 13D/A - BiomX Inc. (0001739174) (Subject)

8-K - BiomX Inc. (0001739174) (Filer)

10-Q - BiomX Inc. (0001739174) (Filer)

NT 10-Q - BiomX Inc. (0001739174) (Filer)

8-K - BiomX Inc. (0001739174) (Filer)

10-K/A - BiomX Inc. (0001739174) (Filer)

8-K - BiomX Inc. (0001739174) (Filer)

SCHEDULE 13D/A - BiomX Inc. (0001739174) (Subject)

8-K - BiomX Inc. (0001739174) (Filer)

S-8 - BiomX Inc. (0001739174) (Filer)

4 - BiomX Inc. (0001739174) (Issuer)

4 - BiomX Inc. (0001739174) (Issuer)

3 - BiomX Inc. (0001739174) (Issuer)

3 - BiomX Inc. (0001739174) (Issuer)

4 - BiomX Inc. (0001739174) (Issuer)

4/A - BiomX Inc. (0001739174) (Issuer)

4/A - BiomX Inc. (0001739174) (Issuer)

4/A - BiomX Inc. (0001739174) (Issuer)

4/A - BiomX Inc. (0001739174) (Issuer)

4/A - BiomX Inc. (0001739174) (Issuer)

NETANYA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the appointment of Prof. Gabby Sarusi as Strategic Advisor to the Company. Prof. Sarusi will advise BiomX as the Company as the company expands its presence in the defense, security, critical infrastructure, and first-response sectors, and drawing on his experience spanning technology development, operational leadership, and long-term strategic planning. His advisory role is expected to support management in evaluating new opportunities and advancing the Company's long-term growth strategy. Prof. Sarusi brings a combination of scientific, defense-industry, commercial, and

NETANYA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the expansion of its Zorronet subsidiary's autonomous C5ISR suite to support fully secure on-premise, hybrid, and closed-loop deployments for defense, security, and critical infrastructure. The expanded offering enables organizations to run the full Zorronet C5ISR suite inside hardened sites, secured intranets, and restricted infrastructure without relying on the public cloud. The expansion reflects growing demand for autonomous command-and-control systems that can function locally inside secured infrastructure, a priority highlighted by US President Donald Trump's push to

NETANYA, Israel, May 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the appointment of Roy Timor-Rousso as Chief Business Officer (CBO), adding senior business & operational leadership as the Company continues building around defense, security, and first response technologies. As a Colonel (res.) in the Israel Defense Forces, Mr. Timor-Rousso's military leadership experience gives him direct understanding of operational command, field coordination, and how technology must serve soldiers and operators on the ground. Bringing on Mr. Timor-Rousso further strengthens BiomX's operating structure with leadership experience in coordinating subsid

NETANYA, Israel, May 06, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company") today announced that its Zorronet subsidiary has launched a secure mobile application that brings its system directly to operators in the field, available now on Google Play and the Apple App Store, and is available for all customers. Zorronet develops AI-powered software that connects cameras, sensors, drones, and IoT devices into a single system. Its technology is already in use in cities and regional councils and across Israel, as well as with Israel Railways, among other organizations. Today, control room operators deal with more data than they can realistically process. Alerts come fr

NETANYA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company") today highlighted the successful deployment of its Zorronet subsidiary in collaboration with Israel Railways, focused on protecting wildlife and safeguarding national infrastructure. Over the past year, a large-scale pilot project, with an investment by Israel Railways of approximately NIS 800,000, was completed and declared a success. The project achieved a success rate of 98% at keeping large animals - including wild boar, foxes, and gazelles - off of railway tracks in the sections it was deployed in. These animals would otherwise have wandered onto the tracks, thereby preserving ecolog

NETANYA, Israel, April 13, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company") today announced that it has accelerated the exercise of its previously disclosed exclusive option and entered into a definitive agreement to acquire a controlling interest in DFSL, an Israeli defense engineering company that develops a proprietary LADAR (Laser Radar)–based detection systems in the perimeter security, critical infrastructure and counter-UAS markets. This transaction marks the next step in BiomX's expansion into the defense sector, adding a second, complementary capability to its portfolio. With DFSL's deployed, high-precision LADAR technology, the company introduces real-t

NETANYA, Israel and REHOVOT, Israel, April 10, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) (the "Company") today announced that it has completed the acquisition of 100% of Zorronet from Water.io (TASE: WATR). This acquisition marks BiomX's entry into the defense, security and rescue sector and establishes a foundation for building a diversified portfolio of defense, rescue, and security capabilities aligned with growing global demand. The acquisition was completed pursuant to a definitive agreement with Water.io. Zorronet is a developer of AI-powered command-and-control software that uses artificial intelligence and machine learning to integrate video analytics, drones, sensors, and I

NETANYA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) today announced that it has entered into an option agreement to acquire control of DFSL, a developer of proprietary LADAR (Laser Radar)–based detection systems for security, defense, and critical infrastructure applications. DFSL's LADAR technology combines laser-based sensing with proprietary AI algorithms to detect and respond to both UAV and ground-based intruders. BiomX intends to exercise the option subject to the closing of the underlying agreement and obtaining shareholder approval as necessary or consideration consisting of a combination of cash, promissory note, shares of common stock and warrants. Separat

NETANYA, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE), today announced the appointment of Dr. Ehud (Udi) Levi to its newly formed Advisory Board.  Dr. Levi will support the Company in evaluating and pursuing strategic alternatives and business opportunities, with an emphasis on security and defense, aerial response systems, and counter-UAS (C-UAS) technologies. This will include identifying and assessing potential partnerships, transactions, and new business directions aligned with the Company's expansion into security and defense applications. Dr. Levi brings more than three decades of experience in Israeli intelligence and national security. He served in Unit 8200

NETANYA, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) (the "Company") today announced that on March 25, 2026, the Company received a notice from the staff of NYSE American LLC (the "NYSE American") that the Company was not in compliance with the NYSE American's continued listing standards in Part 10, Section 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide (the "Company Guide"), requiring a company to have stockholders' equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to have stockholders' equity

NETANYA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the appointment of Prof. Gabby Sarusi as Strategic Advisor to the Company. Prof. Sarusi will advise BiomX as the Company as the company expands its presence in the defense, security, critical infrastructure, and first-response sectors, and drawing on his experience spanning technology development, operational leadership, and long-term strategic planning. His advisory role is expected to support management in evaluating new opportunities and advancing the Company's long-term growth strategy. Prof. Sarusi brings a combination of scientific, defense-industry, commercial, and

NETANYA, Israel, May 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the appointment of Roy Timor-Rousso as Chief Business Officer (CBO), adding senior business & operational leadership as the Company continues building around defense, security, and first response technologies. As a Colonel (res.) in the Israel Defense Forces, Mr. Timor-Rousso's military leadership experience gives him direct understanding of operational command, field coordination, and how technology must serve soldiers and operators on the ground. Bringing on Mr. Timor-Rousso further strengthens BiomX's operating structure with leadership experience in coordinating subsid

NETANYA, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE), today announced the appointment of Dr. Ehud (Udi) Levi to its newly formed Advisory Board.  Dr. Levi will support the Company in evaluating and pursuing strategic alternatives and business opportunities, with an emphasis on security and defense, aerial response systems, and counter-UAS (C-UAS) technologies. This will include identifying and assessing potential partnerships, transactions, and new business directions aligned with the Company's expansion into security and defense applications. Dr. Levi brings more than three decades of experience in Israeli intelligence and national security. He served in Unit 8200

Seasoned financial leaders join BiomX to support strategic execution and advancement of the companyDOVER, Del. and NESS ZIONA, Israel, March 9, 2026 /PRNewswire/ -- BiomX Inc. (NYSE:PHGE), a clinical-stage company developing natural and engineered phage therapies designed to target and destroy harmful bacteria in chronic diseases, today announced the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer. Oster brings extensive experience in corporate strategy, mergers and acquisitions, and operational leadership across capital-intensive industries including energy, infrastructure, and industrial sectors. Throughout his career, he has led complex

CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. "We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company's history," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "For nearly two decades, Susan has held executive positions in both finance

Dr. Basu brings over 20 years of deep technical and management expertise across academia and biotech.Dr. Basu joins the company to lead it into its next development phase, where he will focus on defining strategy, expanding the pipeline and driving corporate development.PAMPLONA, Spain and BARCELONA, Spain, March 19, 2024 /PRNewswire/ -- Telum Therapeutics ('Telum'), a pioneering biotechnology company specializing in the innovation of engineered phage endolysins as novel antibacterial agents to combat multidrug-resistant infections, is announcing the appointment of Subhendu Basu, PhD, as its new Chief Executive Officer. Dr. Basu comes to Telum with an impressive tenure of over two decades in

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Edward L. Williams to its Board of Directors. "We are pleased to welcome Eddie to our Board of Directors," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "As a seasoned executive with extensive board experience, Eddie has successfully led the commercialization and marketing efforts across multiple therapeutic categories for global pharmaceutical companies. His insights, advice and experience will undoubtedly hel

MILAN, Sept. 27, 2021 /PRNewswire/ -- Panakès Partners, the leading Italian venture capital firm in the Life Sciences sector, is pleased to announce that Dr. Rob Woodman has joined Panakès as a Partner, to lead the firm's newly created biotech investment team. The appointment of Dr. Woodman follows the recent first closing at €150 million ($175 million) of Panakès' second fund (named the Purple Fund), which is focused on both Biotech and Medtech. As a result, Panakès is now ideally placed to selectively deploy capital into the next generation of innovative start-ups. Dr. Woodman has global experience in biotech gained at both institutional and corporate venture firms, encompassing de novo s

SC 13G/A - BiomX Inc. (0001739174) (Subject)

SC 13G/A - BiomX Inc. (0001739174) (Subject)

SC 13G/A - BiomX Inc. (0001739174) (Subject)

SC 13D/A - BiomX Inc. (0001739174) (Subject)

SC 13D/A - BiomX Inc. (0001739174) (Subject)

SC 13D/A - BiomX Inc. (0001739174) (Subject)

SC 13G/A - BiomX Inc. (0001739174) (Subject)

SC 13G - BiomX Inc. (0001739174) (Subject)

SC 13D - BiomX Inc. (0001739174) (Subject)

SC 13D/A - BiomX Inc. (0001739174) (Subject)

NETANYA, Israel and REHOVOT, Israel, April 10, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) (the "Company") today announced that it has completed the acquisition of 100% of Zorronet from Water.io (TASE: WATR). This acquisition marks BiomX's entry into the defense, security and rescue sector and establishes a foundation for building a diversified portfolio of defense, rescue, and security capabilities aligned with growing global demand. The acquisition was completed pursuant to a definitive agreement with Water.io. Zorronet is a developer of AI-powered command-and-control software that uses artificial intelligence and machine learning to integrate video analytics, drones, sensors, and I

NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity ("Private Placement") financing for expected gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. About the Private PlacementIn the Private Placement, the Company agreed to issue and sell shares of its Se

Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company's prior Phase 2 success  BiomX expects FDA feedback on BX004 clinical hold imminently; Enrollment and dosing of patients outside the U.S. are continuing in accordance with protocol Positive FDA feedback received in October provided guidance for potential Phase 3 development pathways of BX004 BiomX will host a conference call and webcast today at 8:30 AM ET NESS ZIONA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specif

NESS ZIONA, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it will report its third quarter 2025 financial results and program updates before the open of the U.S. financial markets on Wednesday, November 12, 2025. The Company will host a conference call and a live audio webcast at 8:30 a.m. ET, to discuss the third quarter of 2025 financial results and provide program updates. To ensure you are connected prior to the beginning of the call, BiomX suggests registering a minimum of 5 minutes before the sta

Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning underway for potential registrational study Nature Communications publication of new BX004 Phase 1b/2a data demonstrated further ~500-fold (2.7 log₁₀)2 bacterial reduction versus placebo with no detectable emergence of resistance observed, highlighting strength of BiomX platform capabilitiesPhase 2b trial of BX004 in Cystic Fibrosis (CF) has successfully commenced patient dosing; FDA feedback on real-world evidence strategy expected in H2 2025; Company expects to report topline results in Q1 2026 BiomX will host a conference call and webcast today at 8:00

NESS ZIONA, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it will report its second quarter 2025 financial results and program updates before the open of the U.S. financial markets on Wednesday, August 13, 2025. The Company will host a conference call and a live audio webcast at 8 a.m. ET, to discuss the second quarter of 2025 financial results and provide program updates. To ensure you are connected prior to the beginning of the call, BiomX suggests registering a minimum of 5 minutes before the start

In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO) BX004 Phase 2b study in Cystic Fibrosis (CF) on track to report topline results in Q1 2026 In April 2025, shareholders approved exercise of warrants issued in $12 million in financings announced in February 2025; funds expected to provide runway through topline Phase 2b results for BX004 trial The Company will host a conference call and webcast today at 2:00 PM ET NESS ZIONA, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage ther

NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, May 15, 2025, at 2:00 p.m. ET, to report first quarter 2025 financial results and provide business and program updates. To participate in the conference call, please dial 1-877-407-0724 (U.S.) or +1 201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company's website at www.biomx.com. About BiomXBiomX is a clin

BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13), with a separation from placebo starting at week 7 and a difference greater than 40% by week 10Compared to placebo, BX211 also produced statistically significant1 improvements in both ulcer depth at week 13 (in patients with ulcer depth defined as bone at baseline) (p=0.048), and in reducing the expansion of ulcer area (p=0.017).BiomX is planning for a Phase 2/3 trial of BX211, pending U.S. Food and Drug Administration (FDA) feedback The Company will host a conference call and webcast today at 9:00 AM ET, followed by a

NESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will report fourth quarter and full year 2024 financial results and provide business and program updates on Tuesday, March 25, 2025. A press release reporting the results will be available in the Investors section of the Company's website at www.biomx.com. The Company intends to host a conference call and a live audio webcast on a later date to report fourth quarter and full year 2024 financial results, in conjunction with its expec